Highest-materiality recent filing
PMGC Holdings merges wholly owned subsidiary AGA Precision into A&B Aerospace
On July 2, 2026, AGA Precision Systems LLC merged into A&B Aerospace, Inc., with A&B as survivor.
PMGC sub NorthStrive Defense Tech gets exclusive worldwide license to U.S. Patent 12,291,334 and know-how in aerospace/defense.
Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.
PMGC Holdings shareholders approve staggered board with two classes, effective 2027
Proposal to classify Board into Class I (3-year terms) and Class II (1-year terms) passed with ~6.53M votes for (59.77% of outstanding).
Exclusive worldwide license of US Patent 12,291,334 (multi-media parcel transport) from Florida State University Research Foundation for aerospace/defense field.
Acquired 100% of A&B Aerospace, a precision CNC machining contractor serving aerospace/defense.
PMGC subsidiary NorthStrive files U.S. patent for EL-22 muscle preservation in humans
New U.S. patent application (No. 19/655,160) covers EL-22 as a formulated pharmaceutical product for muscle loss.
PMGC subsidiary NorthStrive secures option for patented GPS-denied drone navigation tech
Secured exclusive option to license U.S. Patent No. 12,277,716 B2 for GPS-denied autonomous drone navigation technology.
SVM Machining signs Long-Term Agreement with Turbo-Jet Products Co. to supply mission-critical aerospace and defense components.
PMGC Holdings secures $40M equity purchase facility for M&A, initial $10M funded
Initial tranche of ~$10 million funded at closing; facility provides up to $40M in pre-paid purchases over 24 months.
AGA Precision Systems signs second long-term supply agreement with Tier 1 aerospace/defense firm
Second LTA in 2026 with a globally recognized Tier 1 aerospace/defense company; first was with Turbo-Jet Products on March 31.
PMGC fully draws $20M equity facility from Streeterville Capital, details acquisitions
Utilized full $20M commitment from equity purchase facility with Streeterville Capital, LLC.
Option covers U.S. Patent No. 12,291,334 for a next-gen drone system operating across air and water.
PMGC forms defense tech subsidiary NorthStrive to target drone and autonomous systems
Wholly owned subsidiary NorthStrive Defense Tech LLC established to focus on defense technology, drones, and autonomous systems.
AGA Precision Systems signs five-year supply deal with Turbo-Jet Products
AGA, wholly owned by PMGC Holdings (ELAB), entered a five-year LTA with Turbo-Jet Products to supply mission-critical aerospace/defense components.
PMGC subsidiary Northstrive and MOA amend license milestones for BLS-M22, add amendment fee
Third Amendment updates development milestones for human health field, including pre-clinical, IND, Phase 1-3, FDA marketing approval.
PMGC subsidiary SVM completes ITAR registration enabling defense contracts
SVM Machining secured ITAR registration from U.S. State Department's Directorate of Defense Trade Controls.
PMGC Holdings sets CEO annual fee at $300k, Chairman at $360k effective Jan 1, 2026
CEO consultant fee (GB Capital Ltd, owned by Graydon Bensler) set at $300,000 per annum.
PMGC Holdings to effect 1-for-6 reverse stock split on March 10, 2026
Reverse stock split at 1:6 ratio, effective March 10, 2026 at 12:00 a.m. ET.
PMGC closes $8.1M secured pre-paid purchase; net proceeds $7.455M; OID $692,569
Fourth Pre-Paid Purchase principal $8,147,569.50; OID $692,569.50; net purchase price $7,455,000.
PMGC subsidiary files 10 US patent applications for EL-22/EL-32 in animal muscle growth
NorthStrive Biosciences, wholly owned by PMGC, filed ten US patent applications expanding EL-22 and EL-32 into animal health and agriculture.
PMGC subsidiary NorthStrive signs exclusive license for EL-22/EL-32 in animal health
Definitive license with Modulant Biosciences for myostatin-engineered probiotic EL-22 and EL-32.
PMGC subsidiary Northstrive grants exclusive animal-health license to Modulant Biosciences
License covers non-human animal health (feed additives) worldwide excluding South Korea.
PMGC Holdings acquires SVM Machining for $2.45M cash plus earnouts up to $1.25M
Base purchase price $2.25M cash ($2M close, $250k holdback) plus $130k cash balance and $69k working capital adjustment.
PMGC Holdings enters $5M Secured Pre-Paid Purchase with Streeterville Capital
Original principal $5,464,500; OID $464,500; net proceeds $4,562,840.
PMGC Holdings enters $3.28M secured pre-paid purchase with 88% discount conversion
Original principal $3,278,700; OID $278,700; net proceeds $2,732,704 after fees.
PMGC Holdings effects 4-for-1 reverse stock split, shares outstanding drop to ~503,713
Reverse split effective Jan 6, 2026 at 9:00 AM ET; every 4 shares combined into 1.
PMGC subsidiaries advance drug discovery program and achieve AS9100 certification
NorthStrive Biosciences advances to Phase III of AI drug discovery program with YuvaBio, targeting muscle preservation via mitochondrial function.
PMGC Holdings shareholders elect all five director nominees at 2025 Annual Meeting
All five director nominees elected with ~99.98% of votes cast (Braeden Lichti, Graydon Bensler, George Kovalyov, Juliana Daley, Jeffrey Parry).
Acquisition price $548,000: $350K to satisfy SBA loan, $28K cash at closing, $170K two-year promissory note at 8% interest.
PMGC Holdings subsidiary AGA Precision Systems obtains ITAR registration
AGA Precision Systems completed ITAR registration, complying with U.S. State Department export controls.
Amends secondment pacts with GB Capital (CEO Graydon Bensler) and Northstrive (Chairman Braeden Lichti); fee set at 30% of employment costs.
Entered into $20M equity line with institutional investor on Sept 23, 2025; initial $5M pre-paid purchase closed Sept 26 for net proceeds of $3.99M.
PMGC Holdings (ELAB) increases authorized shares to 2.5B (2B common, 500M preferred)
Authorized common stock increased to 2,000,000,000 shares; preferred to 500,000,000, effective Sept 15, 2025.
PMGC Holdings announces 3.5-for-1 reverse stock split effective Sept 2, 2025
Reverse stock split at 3.5:1 ratio; effective September 2, 2025 at 9:30 am ET.
PMGC Holdings reduces warrant exercise price to $2.015, raises $1.67M, issues new warrants at $1.89
Gross proceeds of $1,668,218.50 from exercise of Existing Warrants at reduced exercise price of $2.015 per share.
Amends consulting pacts for Chairman Lichti (Northstrive) and CEO Bensler (GB Capital) to add Acquisition Awards.
PMGC terminates electronics LOI, targets CNC machine shops; pending aerospace acquisition
Terminated non-binding LOI dated June 9, 2025 to acquire a U.S. electronics manufacturing company.
PMGC Holdings acquires AGA Precision Systems for $650K; adds ~$1.39M revenue
Acquired 100% of AGA Precision Systems LLC for $650,000 cash on July 18, 2025.
PMGC completes acquisition of Pacific Sun Packaging for $1.15M cash plus $250K earnout
Purchase price $1,148,000 cash plus up to $250,000 earnout contingent on $1,145,915 revenue in 2025 fiscal year.
PMGC signs non-binding LOI to acquire CNC aerospace firm with $4.5M revenue
Target is a U.S.-based, AS9100/ISO 9001-certified CNC machining company founded in 1948.
PMGC signs LOI to acquire profitable CNC shop; Northstrive advances obesity AI collaboration
LOI to acquire California CNC shop with $1.4M revenue, $215K adjusted EBITDA in 2024; AS9100D & ISO 9001:2015 certified.
PMGC signs LOI to acquire profitable electronics manufacturer; $699k revenue, $173k EBITDA
Non-binding LOI to acquire a U.S. contract electronics maker with 40+ years history.
Northstrive grants Modulant exclusive global rights (ex-Korea) to develop/commercialize EL-22 as a probiotic for livestock muscle preservation.
PMGC enters secondment agreement with Northstrive for employee services
Northstrive will second employees to PMGC; employees remain Northstrive staff, not PMGC employees.
PMGC subsidiary Northstrive files four new patent applications for EL-22 and EL-32 programs
Filing covers EL-22 in animals (App. 19/191,246) and EL-32 in obesity as monotherapy and with GLP-1 combos.
PMGC Holdings enters $100M ATM equity facility with Univest; initial $1.74M registered
Entered ATM Sales Agreement with Univest Securities to sell up to $100M of common stock.
PMGC subsidiary Northstrive gets FDA support for IND submission of EL-22 with GLP-1 for obesity
FDA agreed pharmacology studies support EL-22 activity and nonclinical studies appear adequate for safety/activity in overweight/obese humans.
PMGC signs non-binding LOI to acquire profitable IT custom packaging company
Target is a U.S.-based IT custom packaging firm founded in 2011, serving over 300 commercial clients including data centers.
Northstrive (PMGC subsidiary, ticker ELAB) signs exclusive worldwide license for therapies in cardiac diseases and obesity.
On August 1, 2024, Hatem Abou-Sayed MD informed Elevai Labs Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company and as Chief Medical Officer effective as of August 1, 2024.
On August 1, 2024, Hatem Abou-Sayed MD informed Elevai Labs Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company and as Chief Medical Officer effective as of August 1, 2024.
Dr. Jordan Plews, notified the board of directors of the Company (the “Board”) of his intention to resign as chief executive officer of the Company , effective on the close of business on June 21, 2024.
On June 20, 2024, we notified Brenda Buechler, our chief marketing officer, and Christoph Kraneiss, our chief commercial officer that each of them was involuntarily terminated without ‘cause’ or laid off from employment as part of a wider job elimination/restructuring or reduction in force of the Company in order to streamline the Company’s operations and organizational structure.
On June 20, 2024, we notified Brenda Buechler, our chief marketing officer, and Christoph Kraneiss, our chief commercial officer that each of them was involuntarily terminated without ‘cause’ or laid off from employment as part of a wider job elimination/restructuring or reduction in force of the Company in order to streamline the Company’s operations and organizational structure.
the Board appointed Mr. Braeden Lichti, as non-executive chairman and director of the Board
the Board appointed our current chief financial officer and director, Mr. Graydon Bensler, as non-employee Chief Executive Officer of the Company.
the Board appointed Mr. George Kovalyov, as independent director of the Company, as a member of the audit and nomination committee of the Board, and as chairman to the Compensation Committee.
On March 1, 2024, Ms. Crystal Muilenburg, an independent director of the Company notified the board of directors of the Company (the “Board”) of her intention to resign as a director and as chair of the compensation committee of the Company (the “Compensation Committee”) and as a member of the nominating and audit committees of the Company , effective on March 1, 2024.
Max materiality 0.75 · Median 0.55 · Most common event other_material